Pharmafile Logo
Pharmafocus logo
Advanced Search

Debiopharm

Showing 4 posts of 4 posts found.

Merck building

Merck and Debiopharm agree €898m deal to develop head and neck cancer treatments

March 1, 2021
Sales and Marketing Debiopharm, Merck, cancer treatment, head and neck cancer, xevinapant

German science and technology company Merck have agreed a worldwide in-licensing agreement with Debiopharm for the development and commercialisation of …

News

Merck KGaA and Pfizer team up with Debiopharm in lung cancer treatment

October 21, 2016
Medical Communications Debiopharm, Merck KGaA, NSCLC, Pfizer, lung cancer

Debiopharm International, the Swiss-based global biopharmaceutical group of five companies, announced that it would be entering into an agreement with …

News

Debiopharm and Yale University to develop autoimmune treatment

May 5, 2011
Research and Development Debiopharm, Yale University

Debiopharm is teaming up with researchers at Yale University to develop Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory …

News
Pfizer

Pfizer signs ‘personalised’ cancer collaboration

January 15, 2010
Research and Development Cancer, Debiopharm, Pfizer, melanoma, skin cancer, tremelimumab

Pfizer is to co-develop its monoclonal antibody treatment for advanced melanoma with Swiss company Debiopharm. The companies will conduct phase …

News

Latest content

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024

Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy

April 17, 2024

Novartis shares new data about Fabhalta for IgAN treatment

April 16, 2024